Lumanity Reorganizes and Expands Strategic Consulting Capabilities 22-01-2024, 20:00

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15

The Cadmium Yellow Alert: Study Explains the Rapid Deterioration of One of Juan Mirò’s Favourite Colours 6-12-2023, 21:57